Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway

Figure 1

Tree structure reflecting events resulting in costs and potential changes in treatment (i.e., transitions between health states of the Markov model).